News | July 31, 2022
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Subscribe To Our Newsletter & Stay Updated
